Phase 1 Evaluation of CD19-Targeted Allogeneic CAR T Cells in Severe Refractory Systemic Lupus Erythematosus, Rheumatoid Arthritis, Systemic Sclerosis, and Idiopathic Inflammatory Myopathy

The primary objective of this study is to evaluate the safety and tolerability of **CD19-targeted Allogeneic CAR T Cells** derived from healthy donors in participants with severe, refractory autoimmune diseases, including **Systemic Lupus Erythematosus**, **Rheumatoid Arthritis**, **Systemic Sclerosis**, and **Idiopathic Inflammatory Myopathy**. This is clinically relevant as these conditions are characterized by chronic inflammation and immune system dysregulation, often leading to significant morbidity. The use of CAR T cell therapy, which has shown promise in oncology, may offer a novel therapeutic approach for these challenging autoimmune diseases. No secondary objectives are provided in the source data.

The clinical trial involves a total of **40 participants** diagnosed with conditions such as **Systemic Lupus Erythematosus**, **Rheumatoid Arthritis**, **Systemic Sclerosis**, and **Idiopathic Inflammatory Myopathy**. The study population includes both male and female subjects, with an age range corresponding to categories 3 and 4, which typically represent adults and older adults. Participants were selected without targeting any vulnerable populations. The general health status of the participants is not specified, nor are any specific lifestyle considerations such as diet or physical activity mentioned. The sponsor has not provided detailed information regarding the principal inclusion or exclusion criteria for this trial.

The clinical trial is a **Phase 1** study designed to evaluate the safety and efficacy of healthy donor CD19-targeted allogeneic CAR T cells in participants with severe, refractory autoimmune diseases, including **Systemic Lupus Erythematosus**, **Rheumatoid Arthritis**, **Systemic Sclerosis**, and **Idiopathic Inflammatory Myopathy**. The trial employs a randomized, double-blind, controlled design to ensure unbiased results and reliable data. The estimated duration of the trial spans from July 1, 2025, to January 31, 2029, allowing for comprehensive data collection and analysis over this period.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. This initial visit will involve a thorough medical evaluation and baseline data collection. Following successful screening, participants will be randomized into treatment groups and will attend regular follow-up visits to monitor their response to the intervention and any potential adverse effects. These visits will include clinical assessments, laboratory tests, and other relevant evaluations as per the study protocol. The end-of-study visit will mark the conclusion of the participant's involvement, during which final assessments will be conducted to gather comprehensive data on the treatment's impact.

The expected length of participant involvement in the trial is contingent upon the study's timeline and individual response to treatment. Participants may be subject to early termination from the study if they experience significant adverse events, fail to comply with study procedures, or withdraw consent. The trial is structured to prioritize participant safety and the integrity of the collected data, ensuring that any deviations from the protocol are managed according to established guidelines.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is provided in the available data. Consequently, a detailed description of the experimental treatment cannot be formulated based on the current dataset.

Similarly, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, used in the study. Therefore, a description of these elements is not possible with the given data.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also absent from the provided data. As such, no further details can be included in this description.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, indicating an early stage of clinical research primarily focused on safety and dosage. The estimated recruitment start date is July 1, 2025, with an anticipated end date of January 31, 2029. Although specific efficacy parameters such as primary and secondary endpoints are not detailed, typical Phase 1 trials often involve preliminary assessments of efficacy alongside safety evaluations. These assessments may include the use of validated scales, laboratory tests, or patient-reported outcomes to measure changes in relevant clinical markers or symptoms. The schedule for measuring and collecting data is typically aligned with the trial's protocol, ensuring systematic and consistent data collection throughout the study duration. The analysis of efficacy data will be conducted using appropriate statistical methods to determine the potential therapeutic effects of the investigational product. The trial's findings will contribute to the understanding of the investigational product's efficacy profile, guiding future research and development efforts.